A study conducted on mice published in the journalGeroscience has identified the action mechanism of a promising compound against Alzheimer’s disease, developed by the team of Medical Chemistry and Pharmacology at the University of Barcelona. The new drug belongs to a family of molecules that, when bound to imidazole I2 receptors, these cause a reduction in neuroinflammation and an improvement in cognition and other markers of the progression of this disease, the most prevalent among dementias. The results show that these beneficial effects would occur when the calcineurin pathway is modulated. According to the researchers, this preclinical study opens the door to the development of new therapies against Alzheimer’s, a disease that has not been cured yet, and also against other neurodegenerative diseases.
The article results from the collaboration of two research teams from the Faculty of Pharmacy and Food Sciences, led by Mercè Pallàs, member of the Institute of Neurosciences (UBNeuro), and Carmen Escolano, from the Institute of Biomedicine of the UB (IBUB). The study is also signed by UB researchers Christian Griñán Ferré, Foteini Vasilopoulou, Sergio Rodríguez Arévalo, Andrea Bagán and Sònia Abás.
Researchers identify an action mechanism for a drug against Alzheimer‘ disease
Identifiquen el mecanisme d’acció d’un nou fàrmac contra la malaltia d’Alzheimer
Identifican el mecanismo de acción de un nuevo fármaco contra el alzhéimer